Macular Degeneration Clinical Trials

A listing of Macular Degeneration medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 96 clinical trials
Featured trial
C3991004 - Obesity

The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals …

sugars
metformin
diabetes
  • 44 views
  • 30 Jan, 2023
  • 29 locations
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

  • 33 views
  • 07 Oct, 2022
  • 152 locations
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (COAST)

A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

  • 35 views
  • 07 Oct, 2022
  • 158 locations
  • 0 views
  • 16 Oct, 2022
  • 80 locations
  • 1 views
  • 25 Oct, 2022
  • 9 locations
A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD. The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants …

  • 151 views
  • 24 Oct, 2022
  • 103 locations
Safety and Tolerability of RPESC-derived RPE Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.

  • 0 views
  • 04 Oct, 2022
  • 1 location
TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration (nAMD)

This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients. The objective of this study is to

  • 0 views
  • 04 Oct, 2022
  • 1 location
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at two dose levels: 2060 ug and 3090 ug against Aflibercept.

  • 0 views
  • 04 Oct, 2022
  • 4 locations
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment

retinal pigment
optical coherence tomography
atrophy
  • 2 views
  • 13 Oct, 2022
  • 10 locations